Jeremy Halpern, Director of Business Development for the Emerging Companies Group, was quoted in “Young med device firms face tough funding climate” in the Boston Business Journal on April 27. The article discusses the recent drop in VC funding for medical device companies in New England, due to uncertainty over insurer reimbursement strategies and medical device approvals by the FDA. “Venture money has gone upstream, more money is chasing B round deals than early-stage A-round deals,” Jeremy said.